A clinical formulation indicated for Asthma and Breathing. Precise delivery of medication opens bronchial pathways to reduce nocturnal waking and shortness of breath.
A combination maintenance inhaler formulated to manage asthma and COPD symptoms by alleviating airway inflammation and intended to support long-term breathing stability.
Mechanism of Action
Fluticasone reduces lung inflammation, while Salmeterol is a long-acting bronchodilator that keeps airways open by relaxing the muscles around them.
Route of Administration
Inhalation
Onset Time
1–2 weeks
Duration
12 hours
Contraindications
Acute asthma attack, Milk protein allergy (for certain forms), Allergy to fluticasone or salmeterol
Severe Adverse Events
Paradoxical bronchospasm, Pneumonia in COPD patients, Reduced bone density, Glaucoma
Information for Seroflo Inhaler is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
